MX2019009442A - Dendrimeros terapeuticos. - Google Patents

Dendrimeros terapeuticos.

Info

Publication number
MX2019009442A
MX2019009442A MX2019009442A MX2019009442A MX2019009442A MX 2019009442 A MX2019009442 A MX 2019009442A MX 2019009442 A MX2019009442 A MX 2019009442A MX 2019009442 A MX2019009442 A MX 2019009442A MX 2019009442 A MX2019009442 A MX 2019009442A
Authority
MX
Mexico
Prior art keywords
dendrimers
therapeutic
formula
disclosed
dendrimer
Prior art date
Application number
MX2019009442A
Other languages
English (en)
Spanish (es)
Inventor
Bernice Ashford Marianne
Mccoull William
Grant Iain
John Hennessy Edward
Paul Secrist John
Owen David
Kelly Brian
Giannis Michael
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MX2019009442A publication Critical patent/MX2019009442A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02Linear peptides containing at least one abnormal peptide link
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/641Branched, dendritic or hypercomb peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/451Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/02Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids
    • C08G69/08Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids derived from amino-carboxylic acids
    • C08G69/10Alpha-amino-carboxylic acids
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/40Polyamides containing oxygen in the form of ether groups
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G83/00Macromolecular compounds not provided for in groups C08G2/00 - C08G81/00
    • C08G83/002Dendritic macromolecules
    • C08G83/003Dendrimers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Polymers & Plastics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Prostheses (AREA)
  • Pyridine Compounds (AREA)
MX2019009442A 2017-02-22 2018-02-22 Dendrimeros terapeuticos. MX2019009442A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762461983P 2017-02-22 2017-02-22
US201762488151P 2017-04-21 2017-04-21
US201762591823P 2017-11-29 2017-11-29
PCT/EP2018/054420 WO2018154004A1 (en) 2017-02-22 2018-02-22 Therapeutic dendrimers

Publications (1)

Publication Number Publication Date
MX2019009442A true MX2019009442A (es) 2019-10-09

Family

ID=61386833

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019009442A MX2019009442A (es) 2017-02-22 2018-02-22 Dendrimeros terapeuticos.

Country Status (23)

Country Link
US (4) US10314920B2 (enExample)
EP (1) EP3585441A1 (enExample)
JP (1) JP7074761B2 (enExample)
KR (2) KR102544033B1 (enExample)
CN (2) CN110312531A (enExample)
AU (1) AU2018223149B2 (enExample)
BR (1) BR112019016409A2 (enExample)
CA (1) CA3053069A1 (enExample)
CL (1) CL2019002240A1 (enExample)
CO (1) CO2019009722A2 (enExample)
CR (1) CR20190361A (enExample)
DO (1) DOP2019000204A (enExample)
EC (1) ECSP19056271A (enExample)
IL (1) IL268648B (enExample)
JO (1) JOP20190191A1 (enExample)
MX (1) MX2019009442A (enExample)
NI (1) NI201900088A (enExample)
PE (1) PE20191660A1 (enExample)
PH (1) PH12019501896A1 (enExample)
SG (1) SG11201907334QA (enExample)
TW (1) TWI773730B (enExample)
UA (1) UA125655C2 (enExample)
WO (1) WO2018154004A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180326081A1 (en) * 2011-06-06 2018-11-15 Starpharma Pty Ltd Macromolecules
JOP20190191A1 (ar) * 2017-02-22 2019-08-08 Astrazeneca Ab وحدات شجرية علاجية
TWI856967B (zh) 2018-08-17 2024-10-01 瑞典商阿斯特捷利康公司 樹枝狀體配製物
TWI831817B (zh) * 2018-08-17 2024-02-11 瑞典商阿斯特捷利康公司 治療癌症之方法
US20220023290A1 (en) * 2018-11-20 2022-01-27 Starpharma Pty Ltd Therapeutic dendrimer
CN113825397B (zh) 2019-05-07 2023-10-27 赛丹思科大学 用于布撒生物材料的机件
JP2022549680A (ja) * 2019-09-26 2022-11-28 スターファーマ ピーティーワイ エルティーディー 治療用デンドリマー
WO2021113651A2 (en) * 2019-12-04 2021-06-10 Ashvattha Therapeutics, Inc. Dendrimer compositions and methods for drug delivery
TW202206106A (zh) * 2020-04-24 2022-02-16 大陸商上海森輝醫藥有限公司 一類載藥的大分子及其製備方法
CN116075322A (zh) 2020-04-24 2023-05-05 阿什瓦塔治疗股份有限公司 用于治疗重度急性呼吸窘迫综合征的树枝状大分子组合物和方法
EP4180422A4 (en) * 2020-07-10 2024-01-24 Jiangsu Hengrui Pharmaceuticals Co., Ltd. SULFONYL BENZAMIDE DERIVATIVE AND CONJUGATE THEREOF, PROCESS THEREOF AND USE THEREOF
CN116133693A (zh) 2020-08-25 2023-05-16 上海森辉医药有限公司 载药的大分子及其制备方法
WO2022040761A1 (en) * 2020-08-31 2022-03-03 Starpharma Pty Ltd Dendrimer-drug conjugate

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4289872A (en) * 1979-04-06 1981-09-15 Allied Corporation Macromolecular highly branched homogeneous compound based on lysine units
US4410688A (en) * 1981-04-29 1983-10-18 Allied Corporation Macromolecular highly branched homogeneous compound
AR031130A1 (es) 2000-09-20 2003-09-10 Abbott Lab N-acilsulfonamidas promotoras de la apoptosis
US6720338B2 (en) 2000-09-20 2004-04-13 Abbott Laboratories N-acylsulfonamide apoptosis promoters
WO2005049593A2 (en) 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
DK1888550T3 (da) 2005-05-12 2014-09-29 Abbvie Bahamas Ltd Apoptosepromotorer
CA2626865C (en) * 2005-10-25 2014-12-30 Starpharma Pty Limited Macromolecular compounds having controlled stoichiometry
CA2636599C (en) * 2006-01-20 2014-07-15 Starpharma Pty Limited Modified macromolecule
PL2052011T3 (pl) * 2006-08-11 2021-03-08 Starpharma Pty Limited Nakierowany środek terapeutyczny będący dendrymerem polilizynowym
US9127130B2 (en) * 2006-08-11 2015-09-08 Starpharma Pty Ltd. Polylysine dendrimer contrast agent
JP5366817B2 (ja) 2006-11-15 2013-12-11 ジェネンテック, インコーポレイテッド アリールスルホンアミド化合物
US9283302B2 (en) 2011-12-16 2016-03-15 Cormatrix Cardiovascular, Inc. Extracellular matrix encasement structures and methods
WO2009036035A1 (en) 2007-09-10 2009-03-19 Curis, Inc. Bcl-2 inhibitors
EP2306986B1 (en) 2008-06-26 2018-03-21 Prolynx Llc Prodrugs and drug-macromolecule conjugates having controlled drug release rates
US8216549B2 (en) * 2008-07-25 2012-07-10 National Health Research Institutes Method for making a ligand-quantum dot conjugate
RU2497822C2 (ru) 2008-12-05 2013-11-10 Эббви Инк. Селективные к bcl-2 агенты, вызывающие апоптоз, для лечения рака и иммунных заболеваний
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
UY32668A (es) 2009-05-26 2010-12-31 Abbott Lab Agentes inductores de la apoptosis para el tratamiento del cáncer y de enfermedades inmunes y autoinmunes
TWI471321B (zh) 2009-06-08 2015-02-01 亞培公司 Bcl-2族群抑制劑之口服醫藥劑型
WO2011046842A1 (en) * 2009-10-12 2011-04-21 The Regents Of The University Of California Targeted nanoclusters and methods of their use
WO2011140376A1 (en) 2010-05-05 2011-11-10 Prolynx Llc Controlled drug release from dendrimers
JP5977229B2 (ja) 2010-05-05 2016-08-24 プロリンクス リミテッド ライアビリティ カンパニー 巨大分子共役体からの徐放
DK2566334T3 (en) 2010-05-05 2018-07-23 Prolynx Llc MANAGED PHARMACEUTICAL RELEASE FROM SOLID CARRIERS
TWI535712B (zh) 2010-08-06 2016-06-01 阿斯特捷利康公司 化合物
IN2014DN00101A (enExample) * 2011-06-06 2015-05-15 Starpharma Pty Ltd
US20160220689A1 (en) * 2013-09-10 2016-08-04 Starpharma Pty Ltd. Macromolecules of dendrimer-platinum conjugates
US10730999B2 (en) * 2014-06-06 2020-08-04 Starpharma Pty Ltd Dendrimer-drug conjugates
JOP20190191A1 (ar) * 2017-02-22 2019-08-08 Astrazeneca Ab وحدات شجرية علاجية
TWI831817B (zh) * 2018-08-17 2024-02-11 瑞典商阿斯特捷利康公司 治療癌症之方法
TWI856967B (zh) * 2018-08-17 2024-10-01 瑞典商阿斯特捷利康公司 樹枝狀體配製物

Also Published As

Publication number Publication date
AU2018223149B2 (en) 2021-04-01
UA125655C2 (uk) 2022-05-11
IL268648B (en) 2022-04-01
CL2019002240A1 (es) 2019-11-29
KR20230093346A (ko) 2023-06-27
KR102544033B1 (ko) 2023-06-14
JOP20190191A1 (ar) 2019-08-08
US20210060172A1 (en) 2021-03-04
PE20191660A1 (es) 2019-11-11
JP7074761B2 (ja) 2022-05-24
WO2018154004A1 (en) 2018-08-30
TWI773730B (zh) 2022-08-11
KR20190112330A (ko) 2019-10-04
US20180264127A1 (en) 2018-09-20
PH12019501896A1 (en) 2019-10-21
CN117582521A (zh) 2024-02-23
US10888624B2 (en) 2021-01-12
CA3053069A1 (en) 2018-08-30
CN110312531A (zh) 2019-10-08
TW201841659A (zh) 2018-12-01
DOP2019000204A (es) 2019-08-30
WO2018154004A9 (en) 2018-12-27
SG11201907334QA (en) 2019-09-27
US10314920B2 (en) 2019-06-11
IL268648A (en) 2019-10-31
NI201900088A (es) 2020-03-18
JP2020508985A (ja) 2020-03-26
EP3585441A1 (en) 2020-01-01
ECSP19056271A (es) 2019-08-30
AU2018223149A1 (en) 2019-10-03
CO2019009722A2 (es) 2019-09-18
US20240115716A1 (en) 2024-04-11
CR20190361A (es) 2019-09-24
US20200069810A1 (en) 2020-03-05
BR112019016409A2 (pt) 2020-04-07
US11717574B2 (en) 2023-08-08

Similar Documents

Publication Publication Date Title
PH12019501896A1 (en) Therapeutic dendrimers
ZA202405294B (en) Heterocyclic compounds as immunomodulators
ZA202206806B (en) Benzooxazole derivatives as immunomodulators
MX2022005290A (es) Compuestos heterociclicos como inmunomoduladores.
MY210070A (en) Heterocyclic compounds as immunomodulators
PH12018501920A1 (en) Bromodomain inhibitors
PH12018501084B1 (en) Heterocyclic compounds as immunomodulators
MY183036A (en) Amino-triazolopyridine compounds and their use in treating cancer
MX2015017964A (es) Inhibidores de bromodominio.
PH12016501394A1 (en) Compounds for treating patients with ros1 mutant cancer cells
MX2015011984A (es) Inhibidores de bromodominio de dihidro-pirrolopiridinona.
MX2015010829A (es) Compuestos terapeuticos y sus usos.
CA2990457C (en) PYRROLIDINYL AND PIPERIDINYL DERIVATIVES AND RELATED PHARMACEUTICAL COMPOSITIONS USEFUL AS GLS1 INHIBITORS
EA201892311A1 (ru) Производные 2-анилинопиримидина в качестве терапевтических агентов для лечения рака мозга
MX2019004375A (es) Inhibidores de bromodominios.
MX2019004187A (es) Inhibidores de bromodominios.
WO2016112304A8 (en) Furoquinolinediones as inhibitors of tdp2
PH12021550323A1 (en) Dendrimer formulations
MX2015015290A (es) Compuestos furanona como inhibidores de quinasa.
EA201991924A1 (ru) Терапевтические дендримеры
AR111063A1 (es) Dendrímeros terapéuticos
TR201900156T4 (tr) Tüberküloz ve ilgili hastalıkların tedavisi için kinolil hidrazonlar.